MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

Search

Guardant Health Inc

Cerrado

Sector Salud

42.96 -8.44

Resumen

Variación precio

24h

Actual

Mínimo

42.2

Máximo

44

Métricas clave

By Trading Economics

Ingresos

-5.1M

-108M

Ventas

14M

191M

BPA

-0.88

Margen de beneficio

-56.275

Empleados

1,768

EBITDA

-5.3M

-96M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+29.46 upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

6.1B

Apertura anterior

51.4

Cierre anterior

42.96

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

157 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Guardant Health Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 feb 2025, 00:16 UTC

Acciones populares

Stocks to Watch: Alamos Gold, Booking Holdings

22 feb 2025, 16:33 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 15:15 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 14:32 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 13:49 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 13:22 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

21 feb 2025, 23:22 UTC

Principales Noticias

DOGE Aide's IRS Access Won't Include Personal Information -- Update

21 feb 2025, 23:20 UTC

Ganancias

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

21 feb 2025, 22:34 UTC

Charlas de Mercado

L'Oréal Cuts Exposure to Chinese Market, Grows Emerging Markets -- Market Talk

21 feb 2025, 22:12 UTC

Principales Noticias

DOJ Investigates Medicare Billing Practices at UnitedHealth -- 2nd Update

21 feb 2025, 21:54 UTC

Principales Noticias

Why Is Warren Buffett Hoarding So Much Cash? -- 2nd Update

21 feb 2025, 21:51 UTC

Ganancias

Tesla Stock Falls. Recalls and Rivian Are in the News. -- Barrons.com

21 feb 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

21 feb 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 feb 2025, 21:50 UTC

Principales Noticias

DOGE Aide's IRS Access Won't Include Personal Information -- WSJ

21 feb 2025, 21:48 UTC

Charlas de Mercado
Ganancias

L'Oréal Tops Estée Lauder in Luxury U.S. Market, CEO Says -- Market Talk

21 feb 2025, 21:35 UTC

Charlas de Mercado

Bulk of U.S. Imports From Canada Used to Make U.S. Goods -- Market Talk

21 feb 2025, 21:28 UTC

Principales Noticias

Why Is Warren Buffett Hoarding So Much Cash? -- Update

21 feb 2025, 21:24 UTC

Principales Noticias

Major U.S. Stock Indexes Give Up Gains From the Week -- WSJ

21 feb 2025, 21:19 UTC

Charlas de Mercado

Mexico's Inflation Seen Up in Early February -- Market Talk

21 feb 2025, 20:15 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 feb 2025, 20:15 UTC

Charlas de Mercado

JPMorgan Chase Branch Expansion Portends Deposit Growth -- Market Talk

21 feb 2025, 20:05 UTC

Charlas de Mercado

Oil Futures Retreat Into the Weekend Again -- Market Talk

21 feb 2025, 19:58 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Gain -- Market Talk

21 feb 2025, 19:29 UTC

Charlas de Mercado

Gold Slides After Finding Record High -- Market Talk

21 feb 2025, 19:26 UTC

Principales Noticias

Major U.S. Stock Indexes Slip; UnitedHealth Pulls Down DJIA -- WSJ

21 feb 2025, 19:05 UTC

Charlas de Mercado

Business Conditions Seen as Favoring Corporate Credit -- Market Talk

21 feb 2025, 19:02 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

21 feb 2025, 19:02 UTC

Charlas de Mercado

Corporate Credit Expected to Be Hit Unevenly by Trade Wars -- Market Talk

21 feb 2025, 19:00 UTC

Charlas de Mercado

Long-Term Treasury Yields Expected to Rise -- Market Talk

Comparación entre iguales

Cambio de precio

Guardant Health Inc Esperado

Precio Objetivo

By TipRanks

29.46% repunte

Estimación a 12 meses

Media 55.5 USD  29.46%

Máximo 65 USD

Mínimo 34 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Guardant Health Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

18 ratings

18

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

42.21 / 44.47Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

157 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.